Top Wall Street Forecasters Revamp Boston Scientific Expectations Ahead Of Q1 Earnings

Boston Scientific is set to report Q1 EPS of $0.79 on revenue of $5.17 billion, versus $0.75 and $4.66 billion a year ago. The company also disclosed HI-PEITHO trial data for its EKOS Endovascular System on March 28. Shares fell 2.4% to $59.52 ahead of earnings, but the article is largely a factual preview with no new guidance or material surprise.

Analysis

BSX into earnings is more of a quality-vs-expectations event than a pure top-line print. The setup favors a “good numbers, muted reaction” outcome because the stock has already been re-rated on durable procedural growth and investors now need evidence that the company can keep compounding without leaning excessively on transitory stocking or one-time channel help. The more important variable is margin durability: if management confirms operating leverage is still expanding despite ongoing investment in commercialization and clinical data generation, the stock can likely absorb a modest revenue miss better than a guide-down on gross margin or opex cadence.

The HI-PEITHO data matters less for this quarter than for the next 2-4 quarters of specialty-product adoption. Positive read-through would not just help EKOS; it would strengthen the case that Boston Scientific can keep harvesting differentiated adjacencies where clinical proof points translate into faster hospital penetration and less price resistance. The second-order effect is competitive: any evidence of better-than-expected conversion in peripheral or structural heart adjacency categories pressures smaller device peers and makes it harder for competitors to defend share with incremental R&D alone.

The main risk is asymmetry around guidance. A single-quarter beat without an upgrade to full-year assumptions is vulnerable to mean reversion because the stock likely trades on the shape of the 2025-2026 earnings curve, not the print itself. Conversely, a conservative guide on account of procurement timing, Europe softness, or slower procedure normalization would be more damaging than a modest EPS miss, because it would imply the growth engine is intact but the pace of monetization is slipping. The contrarian angle is that the market may be underestimating how much of BSX’s valuation is already supported by a high-quality recurring procedure mix; that makes the downside from an in-line quarter smaller than headline sentiment suggests, while leaving upside limited unless management upgrades the long-range comp narrative.

Key Decisions for Investors

• Hold core long BSX through the print if positioned for 6-12 months; best risk/reward is on a flat-to-up guide, where multiple expansion can outpace a small earnings miss. Trim only if management signals 2025 revenue growth deceleration below consensus by >100 bps.
• For event-driven accounts, buy a short-dated straddle or strangle into earnings if implied move is below the stock’s historical post-print range; the catalyst is guidance, not the quarter, so direction should matter more than delta.
• Pair trade: long BSX / short a lower-quality medtech peer with weaker recurring procedure visibility over the next 1-3 months; BSX should be rewarded if the market continues favoring durable share gains over cyclical recovery stories.
• If the stock sells off 3-5% on an in-line print without guide-down, add tactically on the first pullback; that would likely reflect expectation compression rather than fundamental deterioration, creating favorable entry risk/reward.
• Reduce exposure if management frames HI-PEITHO as data-positive but commercially slow to convert; that would signal a longer monetization runway and lower near-term earnings leverage, which could cap multiple expansion.